Search Clinical Trials
Active, Not Recruiting
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease (External Link)
In order to transplant stem cells we will need to give the patient drugs or high-dose chemotherapy to kill or destroy most of the blood forming and immune cells in …
Baylor Role:
Lead Sponsor
Terminated
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (External Link)
To be treated on this study, we will test the blood to check for viruses, including HIV (the virus that causes AIDS). If the HIV test is positive, a transplant …
Baylor Role:
Lead Sponsor
Completed
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases (External Link)
CAMPATH-1H will be given as a daily IV infusion for three days. Fludarabine will be given as a daily IV infusion for four days. Anti-CD45 will be given as a …
Baylor Role:
Lead Sponsor
Terminated
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (External Link)
Patients will have received a haplo-identical stem cell transplant on our on-going study "CD45 (YTH-24 and YTH-54) and CD52 (Campath 1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell …
Baylor Role:
Lead Sponsor
Terminated
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia (External Link)
Before patients receive any treatments, they will have the following: - Complete history and physical exam - Dental consultation - Bone marrow aspirate - Blood tests - Urinanalysis - Tests …
Baylor Role:
Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (External Link)
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role:
Lead Sponsor
Terminated
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (External Link)
If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by failure to undergo …
Baylor Role:
Lead Sponsor
Terminated
Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate (External Link)
This is a placebo-controlled study which means that the effectiveness of the magnesium medication (the chemical form of which is known as Mg pidolate) will be compared to placebo. A …
Baylor Role:
Lead Sponsor
Terminated
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies (External Link)
To do the stem cell transplant, we must first kill most of the cells in the bone marrow that make the sickle hemoglobin or abnormal blood cells of severe beta …
Baylor Role:
Lead Sponsor
Terminated
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies (External Link)
To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe …
Baylor Role:
Lead Sponsor